ArticleFrontiers in cardiovascular medicine2023
Liuzijue training improves hypertension and modulates gut microbiota profile.
Article in Frontiers in cardiovascular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Modulatory effects of exercise interventions on the gut microbiota in older adults: a systematic review and meta-analysis.The journal of nutrition, health & aging · 2026Pooled it
- Gut microbiota: new links between exercise and disease.Frontiers in microbiology · 2026Review
- Multitarget mechanisms and clinical integration of traditional Chinese medicine in cardiac rehabilitation: a narrative review.Frontiers in cardiovascular medicine · 2026Review
- Mind-body therapies intervention for essential hypertension: network meta-analysis based on the antihypertensive effect.Frontiers in cardiovascular medicine · 2026Review
- Effects of six traditional Chinese mind-body exercises on obesity and cardiovascular risk factors in middle-aged and elderly hypertensive patients: a network Meta-Analysis of 49 RCTs.BMC cardiovascular disorders · 2025Article
- Mechanisms of exercise in preventing cardiovascular diseases: Insights from gut microbiota characteristics in pathological states of cardiovascular diseases.Reviews in endocrine & metabolic disorders · 2025Review
- Article
- Article
- Research Progress on the Correlation Between Hypertension and Gut Microbiota.Journal of multidisciplinary healthcare · 2024Review
- Gut microbiota: a potential new regulator of hypertension.Frontiers in cardiovascular medicine · 2024Review
- Chinese Herbal Medicine Combined With Liuzijue Exercise in Physiological Rehabilitation After Video-assisted Lung Lobectomy for Cancer: A Prospective Propensity Score Matching Study.Integrative cancer therapiesArticle
- Physical activity modifies the association between dietary fiber and hypertension: A cross-sectional study of U.S. adults from NHANES 2007-2018.Science progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Liuzijue training (LZJ) is a traditional exercise integrating breathing meditation and physical exercise, which could prevent and improve hypertension symptoms. Purpose: We aimed to evaluate the therapeutic effect of LZJ on hypertensive patients from the perspectives of blood pressure (BP), vascular endothelial function, immune homeostasis, and gut microbiota. Methods: We conducted a randomized, controlled, single-blind experiment to assess the effect of 12 weeks LZJ in hypertensive patients. We measured the blood pressure level, vascular endothelial function, serum inflammatory factor concentration, and fecal microbial composition of hypertension patients. Results: Compared with aerobic training, LZJ has a more significant effect on serum inflammatory factors (IL-6 and IL-10) and gut microbiota. PCoA analysis showed that LZJ tended to transform the gut microbiota structure of hypertensive subjects into that of healthy people. This process involves significant changes in Bacteroides, Clostridium_sensu_stricto_1, Escherichia-Shigella, Haemophilus, Megamonas, and Parabacteroides. In particular, Bacteroides and Escherichia-Shigella, these bacteria were closely related to the improvement of BP in hypertensive patients. Conclusion: In conclusion, our results confirm that LZJ could be used as an adjuvant treatment for hypertensive patients, which could effectively reduce BP, improve the immune homeostasis and gut microbiota structure in patients, and provide a theoretical reference for the use of LZJ in the clinic. Clinical trial registration: http://www.chictr.org.cn/listbycreater.aspx, identifier: ChiCTR2200066269.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.